Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme—RNase H2—that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast cancer therapies work by causing replication stress, these results suggest RNase H2 is a promising treatment target.